About this episode

This episode discusses updates on clinical diagnostics policies and how pharmacogenomics are enhancing cancer treatment precision.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D. , a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments. PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Policy changes influencing diagnostics (04:09) : Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field. Pharmacogenomic tests improving cancer care (08:14) : Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing. Resources CMS: CLFS & PAMA…

Explore listener stats, chart rankings, contacts and more on the Answers from the Lab podcast page.